Investment Analysts’ Recent Ratings Updates for Guardant Health (GH)

A number of research firms have changed their ratings and price targets for Guardant Health (NASDAQ: GH):

• 10/22/2026 – Guardant Health is now covered by Roth Capital. They set a “buy” rating on the stock.
• 10/15/2026 – Guardant Health had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/12/2026 – Guardant Health had its price target raised by Morgan Stanley from $185.00 to $200.00. They now have an “overweight” rating on the stock.
• 10/7/2026 – Guardant Health had its price target raised by Barclays from $200.00 to $220.00. They now have an “overweight” rating on the stock.
• 10/1/2026 – Guardant Health had its price target raised by Guggenheim from $190.00 to $200.00. They now have a “buy” rating on the stock.
• 9/15/2026 – Guardant Health had its “overweight” rating reaffirmed by Piper Sandler.
• 9/10/2026 – Guardant Health had its “outperform” rating reaffirmed by Sanford C. Bernstein. They now have a $210.00 price target on the stock.
• 9/9/2026 – Guardant Health had its price target raised by UBS Group from $175.00 to $225.00. They now have a “buy” rating on the stock.
• 9/8/2026 – Guardant Health is now covered by Rothschild & Co Redburn. They set a “buy” rating and a $203.00 price target on the stock.
• 9/8/2026 – Guardant Health is now covered by Rothschild & Co Redburn. They set a “buy” rating and a $203.00 price target on the stock.
• 9/2/2026 – Guardant Health had its “buy” rating reaffirmed by BTIG Research. They now have a $195.00 price target on the stock.
• 8/25/2026 – Guardant Health had its “buy” rating reaffirmed by TD Cowen.

Insider Transactions at Guardant Health

In other Guardant Health news, CTO Darya Chudova sold 7,738 shares of the company’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $178.00, for a total value of $1,377,364.00. Following the transaction, the chief technology officer owned 70,635 shares of the company’s stock, valued at approximately $12,573,030. This represents a 9.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Terilyn Monroe sold 46,300 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $165.12, for a total transaction of $7,645,056.00. Following the completion of the transaction, the insider owned 22,979 shares of the company’s stock, valued at approximately $3,794,292.48. The trade was a 66.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 178,940 shares of company stock valued at $30,070,911 in the last 90 days. 5.60% of the stock is owned by corporate insiders.

Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based tests and data solutions designed to help detect cancer, guide treatment decisions and monitor patients over time. Its technologies analyze circulating tumor DNA and other molecular information from blood samples, supporting more accessible and less invasive alternatives to some tissue-based testing approaches.

The company’s products include Guardant360, which helps identify genomic alterations in advanced cancers and may inform targeted treatment selection; Guardant360 Response, designed to assess a patient’s response to therapy; and Guardant Reveal, which is used to detect minimal residual disease and recurrence risk in certain cancers.